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Abstract 
Background: There are multiple copies of mitochondrial DNA (mtDNA) present in each cell type, and they are strictly 
regulated in a cell-specific manner by a group of nuclear-encoded mtDNA-specific replication factors. This strict regu-
lation of mtDNA copy number is mediated by cell-specific DNA methylation of these replication factors. Glioblastoma 
multiforme, HSR-GBM1, cells are hyper-methylated and maintain low mtDNA copy number to support their tumori-
genic status. We have previously shown that when HSR-GBM1 cells with 50% of their original mtDNA content were 
inoculated into mice, tumours grew more aggressively than non-depleted cells. However, when the cells possessed 
only 3% and 0.2% of their original mtDNA content, tumour formation was less frequent and the initiation of tumori-
genesis was significantly delayed. Importantly, the process of tumorigenesis was dependent on mtDNA copy number 
being restored to pre-depletion levels.
Results: By performing whole genome MeDIP-Seq and RNA-Seq on tumours generated from cells possessing 100%, 
50%, 0.3% and 0.2% of their original mtDNA content, we determined that restoration of mtDNA copy number caused 
significant changes to both the nuclear methylome and its transcriptome for each tumour type. The affected genes 
were specifically associated with gene networks and pathways involving behaviour, nervous system development, 
cell differentiation and regulation of transcription and cellular processes. The mtDNA-specific replication factors were 
also modulated.
Conclusions: Our results highlight the bidirectional control of the nuclear and mitochondrial genomes through 
modulation of DNA methylation to control mtDNA copy number, which, in turn, modulates nuclear gene expression 
during tumorigenesis.
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Background
Mammalian cells have multiple copies of the mitochon-
drial genome (mtDNA) within each mitochondrion. 
The human mitochondrial genome is a circular, double-
stranded genome that is 16.6 kb in size. It is essential for 
the production of cellular ATP, as it encodes 13 subunits 
of the electron transfer chain that conducts oxidative 
phosphorylation (OXPHOS) and is the cell’s major gen-
erator of ATP. It also encodes 22 transfer RNAs and 2 
ribosomal RNAs [1].
mtDNA replication is driven by nuclear-encoded 
mtDNA-specific replication factors that translocate to 
the mitochondrion. The primary factor is the mtDNA-
specific polymerase, polymerase gamma [2, 3], which is 
a heterotrimer enzyme composed of a catalytic subunit, 
subunit A (POLG), and two supporting subunits, subu-
nits B (POLG2) [4]. The process of mtDNA replication 
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is also supported by the mitochondrial helicase twin-
kle (TWNK), the single-stranded DNA binding pro-
tein (SSBP1) and the mitochondrial topoisomerase 
(TOP1MT) [5–7]. There are several other key factors 
including mitochondrial transcription factors A (TFAM), 
B1 (TFB1M) and B2 (TFB2M), which generate the pre-
cursor transcript used to initiate mtDNA replication 
[8, 9]. Furthermore, some upstream regulators of these 
mtDNA replication factors are highly involved in mito-
chondrial biogenesis and function. These include nuclear 
respiratory factors 1 and 2 (NRF1/2), peroxisome prolif-
erator-activated receptor γ (PPARG) and its co-activator 
PGC1α (PPARGC1A), the Sirtuin family of genes (SIRT1-
3), and the oestrogen-related receptors (ESRRA/B/G) 
[10–14].
mtDNA replication is strictly regulated during devel-
opment and differentiation, which enables mature cells 
to acquire the requisite numbers of mtDNA copy to 
support their specific functions [15–18]. Initially, this is 
achieved by pluripotent (naïve) cells having established 
the mtDNA set point (reviewed in [19]). These naïve 
cells each possess around 200 copies of mtDNA, which 
promotes glycolysis as the favoured form of energy pro-
duction, and cellular proliferation [20]. These copies of 
mtDNA serve as the initial template for mtDNA replica-
tion, allowing cells to acquire the appropriate numbers of 
mtDNA copy as they differentiate into mature cell types 
[16–18, 20, 21].
The inability to regulate mtDNA copy number affects 
cellular function and impedes developmental potential. 
For example, oocytes at the metaphase II stage that pos-
sess too few copies of mtDNA frequently fail to fertilize 
[22–25]. Likewise, certain types of cancer cells exhibit 
low mtDNA copy number and are unable to successfully 
complete differentiation [16, 18]. Indeed, cancer cells 
mainly rely on aerobic glycolysis for energy production, 
which allows for higher rates of cellular proliferation and 
prevents differentiation from taking place [16]. However, 
when they are induced to differentiate, they appear to be 
trapped in a ‘pseudo-differentiated’ state as they had not 
previously maintained the mtDNA set point and, as a 
result, the nuclear and mitochondrial genomes do not act 
in synchrony [19, 26]. Interestingly, when cancer cells are 
partially depleted of their mtDNA content, they undergo 
dedifferentiation and are then able to replicate mtDNA 
as they undergo differentiation, suggesting that they 
have re-established the mtDNA set point and synchrony 
between the nuclear and mitochondrial genomes [18].
During the early stages of development, the nuclear 
genome undergoes DNA demethylation mediated by 
the ten-eleven translocation methylcytosine dioxyge-
nases (TET enzymes) to erase parental DNA methyla-
tion profiles. De novo DNA methylation then takes place 
to establish a new DNA methylation profile directed by 
the DNA methyltransferase family (DNMTs), which 
primes naïve cells for cellular differentiation [27, 28]. 
To this extent, cell-specific gene expression profiles are 
established during differentiation in synchrony with 
changes to DNA methylation patterns. Likewise, the 
DNA methylation status at exon 2 of POLG is a determi-
nant of when this gene is expressed and, in turn, regu-
lates mtDNA copy number in a cell-specific manner [15, 
16]. This is supported by experiments using DNA dem-
ethylation agents, such as 5-azacytidine [29] and vitamin 
C [30], where modulation of DNA methylation at exon 2 
of POLG increased mtDNA copy number in HSR-GBM1 
cells derived from a glioblastoma multiforme (GBM) 
tumour [16, 18, 31].
The HSR-GBM1 cell line is a high-grade malignant 
GBM cell line that is characterized as being similar to 
stem-like neural precursors and is extensively DNA 
methylated, which contributes to its tumorigenic gene 
profile [32, 33]. However, its hyper-methylated profile 
is not established by the overexpression of the isocitrate 
dehydrogenases (IDH1/2) that harbour onco-muta-
tions, as the alleles for these genes are wild type [34, 
35]. Under normal circumstances, IDH enzymes act on 
the citric acid cycle to generate α-ketoglutarate, which 
is a co-factor of the TET enzymes that modulate DNA 
demethylation patterns [36–40]. However, overexpres-
sion of and mutations to the IDH genes  in GBM result 
in a metabolic switch that produces 2-hydroxyglutarate 
and restricts DNA demethylation induced by the TET 
enzymes [36–40]. Consequently, HSR-GBM1 cells enable 
the analysis of modifications to DNA methylation profiles 
to be undertaken whereby the DNA methylation status 
of the cells is not influenced by mutations to key regu-
lators of DNA demethylation and thus allows the effects 
of mtDNA copy number to be studied independently of 
these influences.
Interestingly, mtDNA depletion of HSR-GBM1 cells 
to varying amounts of mtDNA copy number affected 
tumour progression and frequency when these cells were 
inoculated into mice [18]. Progression and frequency 
were greatest in cells depleted to 50% of their original 
content, but tumour formation was less frequent and 
took significantly longer when cells possessed only 3% 
and 0.2% of their original mtDNA content [18]. Notably, 
mtDNA copy was restored to similar levels during in vivo 
tumorigenesis accompanied by DNA demethylation at 
exon 2 of POLG [17].
In order to determine whether global DNA methyla-
tion profiles were modulated following the restoration 
and maintenance of mtDNA copy number in end point 
tumours, we investigated the DNA methylation profiles 
of GBM tumours derived from HSR-GBM1 cells that 
Page 3 of 18Sun and St John  Epigenetics & Chromatin  (2018) 11:53 
possessed varying amounts of mtDNA copy number 
and exhibited different frequencies and progression in 
tumour formation. We used whole genome methylated 
DNA immunoprecipitation (MeDIP)-Seq. We matched 
the modulated regions with their transcriptional pro-
files to focus on their effects on gene expression. We also 
investigated the mtDNA replication factors to determine 
how they responded to the newly established interactions 
between the nucleus and the mitochondrial genome. Our 
results highlight the bidirectional control of the nuclear 
and mitochondrial genomes through modulation of DNA 
methylation to control mtDNA copy number and gene 
expression in tumours using the HSR-GBM1 cell line as 
a model.
Results
Replenishment of mtDNA copy number
Tumours were previously generated from HSR-GBM1 
cells possessing different levels of mtDNA copy number, 
namely  GBM100 (possessing 100% of their mtDNA con-
tent),  GBM50 (50% mtDNA content),  GBM3 (3% mtDNA 
content) and  GBM0.2 (0.2% mtDNA content) cells [18]. 
Tumours arising from  GBM3 and  GBM0.2 cells had sig-
nificantly delayed initiation and reached end point at 83 
and 90  days, respectively. They had a lower frequency 
of tumour formation (6/12 and 2/12, respectively) com-
pared with  GBM100 tumours, which took 65 days to reach 
end point with tumours forming from 11/12 inoculations 
[18].  GBM50 tumours had accelerated formation (61 days) 
[18]. Furthermore, mtDNA copy number was replen-
ished in each of the end point tumours to pre-depletion 
levels without significant differences (Fig. 1), which high-
lights the need for sufficient mtDNA copy number to 
promote tumorigenesis, and likely explains why delayed 
tumour formation was observed in cells with lower levels 
of mtDNA copy number.
Modifications to DNA methylation resulting 
from re‑establishment of mtDNA copy number 
during tumorigenesis
In order to determine whether DNA methylation of the 
nuclear genome was modulated following re-establish-
ment of mtDNA copy number during tumour progres-
sion, we assessed the global DNA methylation profiles 
of each of the tumour types at end point. Whole genome 
MeDIP-Seq was performed on DNA extracted from 
individual tumours from each cohort to identify key 
regions that might be modulated. Using the MEDIPS 
package, the quality of the sequencing reads was deter-
mined using the saturation and enrichment analyses and 
each achieved high standards, indicating that there was 
sufficient coverage and enrichment of the methylated 
DNA (Additional file  1). Regions with total coverage of 
100 × (minrowsum = 100) or greater reads were used for 
statistical analysis, which is deemed to be a more strin-
gent filter than the default threshold of tenfold coverage 
[31].
A common feature of cancer cells is genomic insta-
bility, which causes significant copy number variation 
(CNV) when compared to healthy controls [41]. CNV 
can also affect the outcomes from comparative analysis 
after MeDIP-Seq, which, if ignored, can introduce false 
positive results due to CNVs inducing higher or lower 
levels of enrichment rather than being reflective of the 
real differences in DNA methylation [41]. Using the Illu-
mina Global Screening Array, no CNVs were identified to 
be significantly different between the tumour groups, as 
assessed using the NEXUS Copy Number Module. This 
negates the potential effect of CNV on the analysis of 
MeDIP-Seq outcomes (see Additional file 2).
Differentially methylated regions (DMRs) were identi-
fied between the  GBM100 tumours and tumours formed 
from cells possessing varying levels of mtDNA. Table  1 
shows the number of DMRs identified in the  GBM50, 
 GBM3 and  GBM0.2 tumours when compared with the 
 GBM100 tumours using different filters for statistical sig-
nificance. With the increase in statistical power (p value) 
from ≤ 0.05, 0.01 to 0.001, fewer DMRs were identified 
in each comparison. Overall, there were fewer DMRs 
identified in the  GBM3 tumours followed by the  GBM50 
tumours whilst there were far more DMRs identified in 
the  GBM0.2 tumours. Using a cut-off p value of 0.001, 













































Fig. 1 Replenishment of mtDNA copy number in the  GBM50,  GBM3 
and  GBM0.2 tumours. Fold change in mtDNA copy number for 
 GBM50,  GBM3 and  GBM0.2 tumours relative to the  GBM100 tumours. 
 GBM100,  GBM50,  GBM3 and  GBM0.2 tumours were harvested at 65 days, 
61 days, 83 days and 90 days after inoculation, respectively. Statistical 
significance was determined using one-way ANOVA (n = 3 tumours 
per group; technical triplicates per sample). No significant differences 
were identified between the groups
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 GBM50 tumours and the  GBM100 tumours, 36 DMRs for 
the  GBM3 tumours and 16,565 DMRs for the  GBM0.2 
tumours. The greater number of DMRs identified for the 
 GBM0.2 tumours indicated that the DNA methylation 
profile for this cohort of tumours was extensively modi-
fied as a result of the increased levels of mtDNA deple-
tion in their initiating cells and subsequent restoration 
during tumorigenesis. We further applied the Bonferroni 
correction to adjust p values to control for false positive 
calls. After correction, there were 143 DMRs identified in 
the  GBM0.2 tumours, but there were no significant DMRs 
identified in the  GBM50 and  GBM3 cohorts of tumours.
Both hyper- and hypo-methylated states were observed 
for tumours derived from cells with lower levels of 
mtDNA copy number. However, the majority of the 
DMRs were hypo-methylated compared to the  GBM100 
tumours (Table  1). There were 31 hyper-methylated 
DMRs (21.68%) identified in the comparison between 
 GBM0.2 and  GBM100 tumours using an adjusted p value of 
0.05. Indeed, the tendency to hypo-methylation was also 
observed in the other tumours. Taking the results iden-
tified using a p value of, for instance, 0.001, only 7.26% 
of the DMRs in the  GBM50 tumours and 44.44% of the 
DMRs in the  GBM3 tumours were hyper-methylated. The 
different proportions of hypo- and hyper-methylation 
further suggest that when tumorigenesis was initiated 
from different levels of mtDNA copy number, different 
patterns of DNA methylation were induced.
The annotation of the DMRs and gene ontology analysis 
for the DMR‑overlapping genes
Firstly, the annotation of genomic regions was performed 
on the four groups of DMRs identified using the filters of 
a p value ≤ 0.001 and an adjusted p value ≤ 0.05  [GBM50 
vs  GBM100 (p ≤ 0.001),  GBM3 vs  GBM100 (p ≤ 0.001), 
 GBM0.2 vs  GBM100 (p ≤ 0.001) and  GBM0.2 vs  GBM100 
(adjusted p ≤ 0.05)]. Overall, the results showed that over 
49% of the DMRs were enriched in intragenic regions, 
namely exons, introns and promoter regions, and they 
were the most enriched regions (Fig.  2a–d). Each of 
these four groups of DMRs showed the greatest enrich-
ment at introns, which was 52.51% of the  GBM50 DMRs 
(Fig. 2a), 39.22% of the  GBM3 DMRs (Fig. 2b), 34.73% of 
the  GBM0.2 DMRs (Fig. 2c; p ≤ 0.001) and 35.94% of the 
 GBM0.2 DMRs (Fig. 2d; adjusted p ≤ 0.05). For the  GBM50 
and  GBM3 DMRs, the second most enriched regions 
were the distal intergenic regions, which were enriched 
at 22.35% and 37.25%, respectively (Fig.  2a, b). Interest-
ingly, for the  GBM0.2 DMRs, identified using the filters 
of p ≤ 0.001 and adjusted p ≤ 0.05, similar patterns were 
observed regardless of the numbers of DMRs (Fig.  2c, 
d). In contrast to the  GBM50 and  GBM3 DMRs, the sec-
ond most enriched region for the  GBM0.2 DMRs was the 
promoter regions, which were 23.60% and 25.81% of the 
DMRs after filtering at p ≤ 0.001 and adjusted p ≤ 0.05, 
respectively (Fig. 2c, d). The distal intergenic regions were 
ranked third accounting for 16.51% and 18.89% of the 
 GBM0.2 DMRs identified using the filters of p ≤ 0.001 and 
adjusted p ≤ 0.05, respectively (Fig.  2c, d). Untranslated 
regions (UTRs), downstream regions of genes and super 
enhancers accounted for less than 14% of the DMRs in 
each comparison. Interestingly, over 80% of the identified 
DMRs overlapped with topologically associating domains 
(TADs) that interact with other genomic regions and are 
considered to be the regulatory units of the genome [42].
To understand the related functions of the DMRs, 
functional classification and statistical overrepresenta-
tion analyses were performed on the DMR-overlapping 
genes using the PANTHER Classification System. The 
functional classification of the DMR-overlapping genes 
showed that the  GBM50 and  GBM3 tumours mostly 
clustered into cellular and metabolic processes (Fig.  3). 
Furthermore, the pathways of biological regulation, 
localization, response to stimuli and developmental pro-
cesses were present in both cohorts (Fig. 3). Due to the 
large number of DMR-overlapping genes identified in the 
 GBM0.2 tumours using the two different filters, statistical 
overrepresentation analysis was, therefore, performed. 
Interestingly, the biological processes enriched in the 
DMR-overlapping genes showed strong associations 
with developmental processes, especially in the DMR-
overlapping genes identified with an adjusted p value of 
0.05 (Table  2). The common developmental pathways 
identified in both analyses (shown in italics) included 
developmental, nervous system development and cell 
differentiation processes (Table 2). This is in line with a 
previous finding that, after partial mtDNA depletion with 
Table 1 The number of  DMRs identified in  tumours (n = 3 per  group) formed from  depleted cells compared with  non-
depleted cells
The ratio of hyper- and hypo-methylated DMRs (expressed as percentages) is shown in brackets
Comparisons p ≤ 0.05 p ≤ 0.01 p ≤ 0.001 Adj. p ≤ 0.05
GBM50 versus  GBM100 8980 (16.85%: 83.15%) 1135 (10.57%: 89.43%) 124 (7.26%: 92.74%) –
GBM3 versus  GBM100 4940 (34.76%: 65.24%) 597 (41.88%: 58.12%) 36 (44.44%: 55.56%) –
GBM0.2 versus  GBM100 51,366 (11.25%: 88.75%) 34,060 (3.66%: 96.34%) 16,565 (2.14%: 97.86%) 143 (21.68%: 78.32%)
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7 and 14-day ddC treatment, differentiation was able to 
take place in the GBM cells [18]. Moreover, regulation 
of transcription from the RNA polymerase II promoter 
was found to be commonly modulated, which reflected 
the potential for transcriptional changes that could result 
from the DMRs.
Validation of the gene expression of the regulators of DNA 
methylation
DNA methyltransferases (DNMTs), namely 
DNMT1/3A/3B, are responsible for catalysing DNA 
methylation at cytosines by converting them to 5-methyl-
cytosines (5mC). On the other hand, the ten-eleven 
translocation (TET) enzymes, namely TET1/2/3, can 
demethylate 5mC to 5-hydroxymethylcytosine (5hmC) 
[27, 28]. The changes to these DNA methylation and 
demethylation factors can provide insights into how 
the changes to the DNA methylation profiles occurred. 
Therefore, the gene expression levels of the DNA methyl-
ation regulators were assessed using a custom-made Flui-
digm qPCR array (Fig. 4). There was ≥ 1.5-fold change in 
expression of DNMT1 in  GBM50 and  GBM0.2 tumours, 
suggesting that the reduction in mtDNA copy number 
strongly induced DNA demethylation in the tumours, 
and is probably the major reason why the majority of 
regions were hypo-methylated (Table  1). DNMT3A was 
also significantly down-regulated by over 1.5-fold in the 
 GBM50 tumours (Fig. 4). None of the DNA methylation 
factors was found to be differentially expressed in the 
 GBM3 tumours compared with the  GBM100 tumours, 
which further supported the results that fewer DMRs 
were identified in this group. The expression of TET1 
showed a trend of up-regulation only in the  GBM0.2 
tumours. As there was a higher percentage of hyper-
DMRs in the  GBM0.2 tumours, the up-regulation of TET1 
might be a response to counter the increased hyper-
methylation observed.
Furthermore, it has been reported that the genomes of 
low grade and secondary glioblastomas are extensively 
methylated to support the tumorigenic transcriptome 
that they exhibit [32, 38–40, 43]. This is further supported 
by the findings that the overexpression of the mutated 
isocitrate dehydrogenase (IDH1/2) in the citric acid cycle 
inhibits the activity of TET2 and thus contributes to the 
hyper-methylated genome [36–40]. However, the HSR-
GBM cell line possesses wild-type alleles for IDH1/2 [34, 
35], which makes it an excellent model to investigate the 
impact of mtDNA content in tumour-initiating cells on 
DNA methylation patterns during tumorigenesis, espe-
cially as non-mutated IDH1 has been shown to promote 
cell growth in GBM [44]. We, therefore, investigated the 
expression of IDH1/2 in these tumours and found that 
expression for both genes was down-regulated in the 
 GBM50 tumours (Fig. 4), which likely reduced their abil-
ity to induce hyper-methylation and supports the hypo-
methylation observed in these tumours.
Fig. 2 Annotations of the DMRs. Based on their genomic locations, 
DMRs identified in the comparison: a  GBM50 versus  GBM100 
(p ≤ 0.001); b  GBM3 versus  GBM100 (p ≤ 0.001); c  GBM0.2 versus  GBM100 
(p ≤ 0.001); and d  GBM0.2 versus  GBM100 (adjusted. p ≤ 0.05) were 
classified into promoters, exons, introns, UTRs, downstream regions, 
distal intergenic regions and super enhancers using the ChIPSeeker 
package (n = 3 tumours per group). DMR-overlapping regions in 
brown signify promoter regions, violet-red indicates exons, green 
indicates introns, blue indicates promoters, teal represents UTRs, blue 
represents downstream regions, orange indicates intergenic regions, 
and pink indicates super enhancers. The percentage of each group is 
indicated in the key to each figure
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DMR‑overlapping differentially expressed genes 
and differentiation markers after restoration 
of tumorigenic capacity
To investigate which genes changed their patterns of 
expression in response to the altered levels of DNA 
methylation, we compared the identified DMRs with the 
differentially expressed genes previously reported on the 
same samples [17]. We focused on the DMRs identified 
using an adjusted p value of 0.05, which were consid-
ered to be the genomic regions that had undergone most 
significant changes in DNA methylation. There were 9 
DMR-overlapping differentially expressed genes, namely 
BAIAP2, L3MBT1L, KCNC1, GPSM1, SLC27A1, MAF, 
OGFR, MICALL2 and RHOT2 (Fig.  5a). The changes to 
the levels of gene expression were further validated for 
these genes (Fig.  5a). Interestingly, the  GBM3 tumours, 
with the least number of DMRs, showed more variable 
patterns in expression amongst the DMR-overlapping 
genes when compared with the  GBM100 tumours. RHOT2 
and OGFR were significantly up-regulated in the  GBM3 
tumours (p < 0.05 and p < 0.01, respectively). The greater 
modification that occurred in the DNA methylation pro-
files of the  GBM50 and  GBM0.2 tumours promoted gene 
expression profiles more similar to the tumorigenic fea-
tures of the  GBM100 tumours, whereas less modification 
in the  GBM3 tumours failed to mimic the transcriptional 
changes in these DMR-overlapping genes.
As the DMRs were found to be tightly associated with 
developmental processes (Fig.  3 and Table  2), we also 
focused on the neural markers and genes in neurogen-
esis that have been reported in cells having undergone 
mtDNA depletion to the same levels as those used to 
form tumours [18]. Indeed, it has been previously shown 
that  the partial mtDNA depletion of GBM cells could 
lead to increased expression of genes associated with 
early developmental processes [18]. In tumours formed 
from these cells, an overview of gene expression identi-
fied by RNA-Seq data is shown (Fig.  5b). Both up-reg-
ulation and down-regulation were observed. To make 
a comparison between the in vivo tumours and in vitro 
cells, the negative regulator of cell proliferation ALK was 
found to be down-regulated in the mtDNA-depleted 
tumours. However, ALK was found to be up-regulated in 
the mtDNA-depleted cultured cells. Likewise, the regu-
lators of cell differentiation and proliferation, VEGFA, 
DLG4, CDK, NRP2 and ACHE, were also found to be 
down-regulated in the mtDNA-depleted tumours but 
presented higher levels of expression in the cells. The 
regulators of transcription and differentiation, ASCL1 
and DLL1 in the Notch signalling pathway, were found 
to be up-regulated in the mtDNA-depleted tumours but 
down-regulated in the cells. The regulator of synaptogen-
esis, APOE, was found to be up-regulated in the  GBM50 
and  GBM3 tumours, but down-regulated in the  GBM0.2 
tumours and the mtDNA-depleted cells. Moreover, 
FGF13, SEMA4D, PAPD6B and NRCAM were found to 
be commonly up-regulated in both cells and tumours. As 
the cells recovered their tumorigenicity after restoration 
of mtDNA copy number in vivo, the shifts in gene expres-
sion between the tumours and the cells indicated that the 
restoration and maintenance of mtDNA copy number in 
Fig. 3 Functional classification analysis of the DMR-overlapping genes in the  GBM50 and  GBM3 tumours. DMR-overlapping genes in: a  GBM50 
tumours; and b  GBM3 tumours were classified into subgroups based on their associated biological processes using the PANTHER system
Page 7 of 18Sun and St John  Epigenetics & Chromatin  (2018) 11:53 



















191/548 1.47 6.12E−06 9.95E−05  Cell differ-
entiation 
(GO:0030154)
9/459 3.93 5.42E−04 4.41E−02
 Nervous system 
development 
(GO:0007399)
113/314 1.52 1.88E−04 1.76E−03  Nervous system 
Development 
(GO:0007399)
7/238 5.89 2.23E−04 5.45E−02












10/548 3.66 4.61E−04 5.63E−02
 Cellular process 
(GO:0009987)
57/7905 1.45 5.54E−04 2.70E−02
 Behaviour 
(GO:0007610)




537/1501 1.51 1.01E−16 2.46E−14
 Sensory percep-
tion of smell 
(GO:0007608)










3/144 0.09 2.98E−10 1.21E−08
 B cell mediated 
immunity 
(GO:0019724)








96/212 1.91 3.82E−07 8.46E−06
 Cell recognition 
(GO:0008037)




109/269 1.71 4.74E−06 8.27E−05
 Phagocytosis 
(GO:0006909)













124/356 1.47 2.72E−04 2.21E−03
Page 8 of 18Sun and St John  Epigenetics & Chromatin  (2018) 11:53 
tumorigenesis is tightly associated with the regulation of 
differentiation.
Modulation of the mtDNA replication factors 
for the maintenance of mtDNA copy number 
in tumorigenesis
As mtDNA copy number was replenished to similar 
levels in each of the tumour types (Fig.  1), we deter-
mined how the mtDNA-specific replication factors were 
affected. In total, 20 known mtDNA replication factors 
were screened for differentially methylated intragenic 
CpG islands (CGIs). The fold changes in relative meth-
ylation scores for the  GBM100 tumours of 28 promoter 
and gene-body CGIs within the mtDNA replication fac-
tors were plotted (Fig.  6a). An increasing trend in fold 
changes was observed from the  GBM50 to the  GBM0.2 
tumours. Particularly, for the CGIs, higher levels of meth-
ylation were found in the  GBM50 tumours compared to 
the  GBM100 tumours (shown in red blocks) and the fold 
changes generally increased to an even higher level in 
the  GBM0.2 tumours. This trend was mostly observed 
amongst the gene-body CGIs. For the CGIs that were 
more hypo-methylated in the  GBM50 tumours than the 
 GBM100 tumours (shown in blue blocks), the levels of 
DNA demethylation were indicative of minor shifts in the 
 GBM0.2 tumours.
Furthermore, the gene expression levels were also 
assessed using a Fluidigm qPCR array (Fig. 6b). Overall, 
the levels of expression of the mtDNA replication factors 
in the tumours formed from cells possessing varying lev-
els of mtDNA were found to be down-regulated, which 
likely restricts mtDNA replication during tumorigenesis 
after the restoration of mtDNA copy number to its origi-
nal levels. ESRRA, NRF1, POLG, PPARGCA1 and SIRT1 
were identified to be significantly down-regulated in all of 
the mtDNA-depleted tumours. The mtDNA replication 















 Cell adhesion 
(GO:0007155)

















43/99 1.84 1.25E−03 8.73E−03























121/382 1.34 5.92E−03 3.28E−02
Page 9 of 18Sun and St John  Epigenetics & Chromatin  (2018) 11:53 
factors POLG2, TOP1  MT and TWNK were also found 
to be down-regulated in the  GBM50 and  GBM3 tumours. 
Moreover, the key mtDNA transcription factors POL-
RMT, TFAM, TFB1M and TFB2M were down-regulated 
in the  GBM50 and  GBM3 tumours. NRF2 and SIRT3 were 
only down-regulated in the  GBM50 tumours. The hypoxia 
regulator STAT3 was found to be significantly down-reg-
ulated in the  GBM50 and  GBM0.2 tumours. ESRRG was 
only down-regulated in the  GBM3 tumours. This indi-
cates that mtDNA replenishment had been completed 
and the low levels of expression of the mtDNA replica-
tion factors were indicative of mtDNA turnover dur-
ing cell division rather than the active repopulation of 
depleted cells with mtDNA.
Discussion
We have shown that bidirectional cooperation between 
the nuclear and mitochondrial genomes is important 
for tumour formation. To this extent, the DNA methyla-
tion and gene expression profiles of the nuclear genome 
were extensively modulated following the restoration of 
mtDNA copy number to pre-depletion levels in tumours 
that developed to end point. Whilst it is conceivable that 
the mtDNA depletion process did not reduce mtDNA 
copy in individual cells from each group uniformly, it is 
unlikely that this occurred. If a small population of cells 
with higher mtDNA copy number had been selected for, 
there would have been greater similarity amongst the 
DNA methylation and gene expression profiles across 
the groups. However, cells from each group exhibited 
distinct gene expression profiles prior to inoculation [18] 
and DNA methylation and gene expression profiles as 
end point tumours.
The restoration of mtDNA copy number can be 
achieved through the cell’s own mtDNA replication 
machinery or the horizontal transfer of mitochondria 
from surrounding cells [17, 45, 46]. It was previously 
shown that the same tumours possessed only human 
mtDNA and not mouse mtDNA from the surrounding 
stroma [47]. However, the restoration of mtDNA copy 
number also involved the accumulation of mtDNA vari-
ants, which increased in number as a function of the 
degree of restoration of mtDNA copy number. Each of 
the tumours exhibited a gain in de novo variants primar-
ily associated with ND4 and ND6, which encode subu-
nits of complex I of the electron transfer chain, and the 
D-loop. However, these variants have been identified in 
other GBM cell lines [47]. Consequently, the presence 
and modulation of mtDNA are important to tumorigen-
esis given that cells require mtDNA to be fully functional 
[48].
The effects of DNA methylation on transcription vary 
dependent on the location of the methylated sites. Meth-
ylated CGIs within the promoter regions are known to 
repress transcription [49], whereas methylation within 
gene bodies correlates positively and negatively with 
transcriptional elongation [50]. In our work, the degree 
of restoration of mtDNA copy number differentially 
affected the levels of DNA methylation in the end point 
tumours. However, the majority of the DMRs were 
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Fig. 4 Differential expression of the regulators of DNA methylation. Bars represent the mean of the relative quantification levels relative to the 
 GBM100 tumours (relative expression = 1). Error bars show SEM (n = 3 tumours per group; technical replicates per sample). Statistical significance 
was determined by One-way ANOVA. *, ** and *** p values < 0.05, 0.01 and 0.001, respectively
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high enrichment in the intragenic regions, namely pro-
moters, exons and introns, there were differences in the 
numbers of DMRs affected and their distribution across 
the nuclear genome, especially for the promoter and 
exon regions amongst the comparisons. The DMRs in 
the  GBM50 and  GBM0.2 tumours also overlapped with 
several enhancers, which are documented to contribute 
to tumour progression and cancer cell plasticity [51]. 
Furthermore, over 80% of the DMRs overlapped with 
TADs, the regulatory units of the genome [42], which 
suggests that their modulation could affect the structural 
formation and, therefore, genetic activities of the genome 
[42].
These outcomes are likely mediated by the down-reg-
ulation in levels of expression of the DNA methyltrans-
ferases, especially DNMT1. For the  GBM0.2 tumours, 
DNA demethylation was further enhanced by the up-
regulation of TET1, which mediates the transition from 
5mC to 5hmC [52], resulting in these tumours being 
most hypo-methylated. IDH1 and IDH2, the cyto-
plasmic and mitochondrial isoforms respectively, had 

























































































































Fig. 5 Transcriptional profiles of DMR-overlapping differentially expressed genes and markers of neurogenesis and neural stem cells. a Differential 
expression of the DMR-overlapping differentially expressed genes. Bars represent the mean of the relative quantification levels relative to the 
 GBM100 tumours (relative expression = 1). Statistical significance was determined by One-way ANOVA. Error bars show SEM (n = 3 per group; 
technical triplicates per sample). *, ** p values < 0.05 and 0.01, respectively. b Heatmap of markers of neurogenesis and neural stem cells from the 
RNA-Seq profiles. For the  GBM50,  GBM3 and  GBM0.2 cohorts, the fold changes (log2) of read counts to the mean value of the  GBM100 cohort were 
plotted. The colour scheme from blue, white to red represents the level of expression from twofold down-regulation to twofold up-regulation
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mtDNA-depleted cells than  GBM100 tumours. This sug-
gests that α-ketoglutarate could continue to act as a co-
factor of the TET enzymes and did not induce a switch 
to 2-hydroxyglutarate to promote hyper-methylation 
[43, 44, 53]. This is consistent with HSR-GBM1 cells 
possessing wild type copies of the IDH genes [34, 35], 
which is common in high-grade (IV) astrocytomas [38, 
40, 44]. One-carbon metabolism also takes place in the 
mitochondria resulting in the generation of S-adeno-
sylmethionine, the universal methyl group donor [54]. 
S-adenosylmethionine is present at abnormal levels in 
cancer cells and could affect DNA methylation profiles 
during tumorigenesis [54]. We would anticipate that 
S-adenosylmethionine activity was down-regulated as a 
result of mtDNA depletion, which reduces mitochon-
drial function [55], and, thus, promotes the hypo-meth-
ylated state of the resultant tumours.
During early development, large-scale DNA dem-
ethylation takes place to reset the nuclear genome to 
a naïve state [27, 28]. This is coupled with the strict 
regulation of mtDNA copy number to establish the 

























































































































Fig. 6 Overview of the changes to DNA methylation and transcription of the mtDNA replication factors. a DNA methylation levels of the intragenic 
CGIs associated with the mtDNA replication factors. Fold changes in relative methylation scores to the  GBM100 tumours were plotted for the three 
biological replicates from the  GBM50,  GBM3 and  GBM0.2 cohorts. The colour scheme from blue, white to red represents the level of DNA methylation 
from low to high. “P”, “E” and “I” following each gene name indicates CGIs that are located at the promoter regions, exons and introns, respectively. b 
Differential expression of the mtDNA replication factors. Bars represent the mean of the relative quantification levels relative to the  GBM100 tumours 
(relative expression = 1). Error bars show SEM (n = 3 tumours per group; technical replicates per sample). Statistical significance was determined by 
one-way ANOVA. *, ** and *** p values < 0.05, 0.01 and 0.001, respectively
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act in tandem to overcome a number of molecular 
check points at different stages of development, which 
include mtDNA replication turnover events [56]. 
Indeed, Polg-/- mice do not possess sufficient mtDNA 
at E6.5 and cannot initiate mtDNA replication at this 
key developmental check point and, consequently, die 
[57]. Likewise, somatic cells reprogrammed to a naïve, 
pluripotent state, similar to embryonic stem cells, can 
fail to re-establish the mtDNA set point and lose their 
differentiation potential [56]. HSR-GBM1 cells are 
cancer stem cells that express key early neural mark-
ers, maintain low mtDNA copy number and use gly-
colysis for energy production, which are typical facets 
of a stem cell [33]. However, when they are induced to 
differentiate into high OXPHOS-derived ATP requir-
ing cells, for example neurons and astrocytes, they fail 
to replicate mtDNA in synchrony with changes to the 
nuclear genome and their progress stalls [56]. Never-
theless, mtDNA partially depleted HSR-GBM1 cells can 
re-establish their mtDNA set point and expand their 
mtDNA copy number in order to complete differentia-
tion [18] (please refer to Fig. 7 ‘in vitro’). However, the 
degree of restoration of mtDNA copy number influ-
enced the differentiation and transcriptional potentials 
of the cells as determined by RNA-Seq analysis of end 
point tumours. The most affected networks between 
the  GBM100 and the  GBM0.2 and  GBM3 tumours were 
cellular development, cellular growth and proliferation, 
whilst cancer, cell cycle and cellular development were 
most affected in the  GBM50 tumours [17].
Although the  GBM50 tumours are more aggressive, 
they appear to restrict mtDNA replenishment to pre-
depletion levels, which ensures that the balance between 
mtDNA copy number and the methylation of the chro-
mosomal genome is at levels that promote tumorigenesis, 
as is the case for the  GBM3 and  GBM0.2 tumours. From 
a mtDNA perspective, there is increased hyper-methyl-
ation in the majority of gene-body CGIs of the mtDNA 
replication factors of the mtDNA-depleted tumours 
compared with the  GBM100 tumours. This is exemplified 
by increased methylation at exon 2 of POLG and exon 8 
of TOP1MT and decreased levels of expression for these 
two genes, which are known to regulate mtDNA copy 
number in a cell-specific manner through DNA methyla-
tion at these intragenic regions [15, 16, 31]. Interestingly, 
the use of DNA methylation agents, such as 5-Azacyti-
dine and Vitamin C, on cultured HSR-GBM1 and repro-
grammed somatic cells can restore mtDNA replication 
turnover events and promote differentiation [16], which 
likely explains the use of these agents in clinical settings 
for cancer patients [58, 59].
The DMR-overlapping genes affected a variety of bio-
logical processes. In the  GBM50 and  GBM3 tumours, the 
primary effects were on cellular and metabolic processes. 
Fig. 7 Modulation of mtDNA copy number affects the fate of HSR-GBM1 cells. In the in vitro model of HSR-GBM1 cells, depletion of mtDNA (yellow 
arrow) for 7/14 days results in demethylation of the nuclear genome (green) and rescues differentiation to astrocytes that is otherwise blocked 
(green arrow). In the in vivo model of HSR-GBM1 cells, varying levels of depletion result in different frequencies of progression to tumorigenesis 
(orange arrow). 50% depletion accelerated tumorigenesis (thicker orange arrow), whereas further depletion slowed the initiation of tumorigenesis 
by modulating differentiation networks, nuclear gene expression and the mtDNA replication factors
Page 13 of 18Sun and St John  Epigenetics & Chromatin  (2018) 11:53 
In the  GBM0.2 tumours, developmental processes were 
more overrepresented, including cell differentiation and 
nervous system development. Of the nine DMR-overlap-
ping differentially expressed genes, four were specific to 
neurogenesis. SLC27A1 was significantly down-regulated 
in a SOX2-knockdown GBM cell line characterized by 
abolished dedifferentiation and decreased tumorigen-
esis [60]. Mutations in KCNC1 have been reported as 
the driving cause for progressive myoclonus epilepsies 
[61]. Indeed, a number of DNA methylation signatures 
have been identified in several neurodevelopmental syn-
dromes, including Coffin–Siris, Kabuki and CHARGE 
syndromes, which are implicated in a variety of cancers 
[62, 63].
Although the  GBM3 tumours presented with the least 
number of DMRs, they had more variable patterns of 
expression amongst the DMR-overlapping genes. For 
example, RHOT2 and OGFR were significantly up-reg-
ulated in the  GBM3 tumours. RHOT2 is a miro GTPase 
that regulates mitochondrial transport, distribution and 
dynamics, especially in neurodegenerative disorders 
[64, 65], and is differentially expressed in different types 
 (CD133+ and  CD133−) of GBM stem cells [66]. It is 
usually only expressed in type I GBM cancer stem cells 
and is co-expressed with the stem cell markers SOX2, 
SOX11 and OLIG2 [66]. This indicates the expression of 
RHOT2 is important for regulating mitochondria and 
their dynamics during early development, which requires 
the presence of mtDNA given that cells need mtDNA to 
be fully functional [48]. On the other hand, OGFR is a 
negative regulator of cell proliferation and reduces pro-
liferation of astrocytes in cell culture [67]. Consequently, 
 GBM3 tumours differentially expressed two genes associ-
ated with different stages of development unlike the other 
tumour types. Nevertheless, the greater levels of modifi-
cation that occurred in the DNA methylation profiles of 
the  GBM50 and  GBM0.2 tumours promoted gene expres-
sion profiles more indicative of the tumorigenic features 
of the  GBM100 tumours. A similar situation has been 
observed in tumour cell lines possessing the same chro-
mosomal background but different mtDNA haplotypes 
where early tumours from each haplotype expressed a 
distinct set of genes [68]. However, in this case, a series 
of commonly expressed genes were expressed again 
highlighting how the mitochondrial genome can affect 
tumorigenesis.
It is evident that  GBM0.2 cells, which had undergone 
a longer period of mtDNA depletion through an agent 
that specifically targets POLG from interacting with the 
mitochondrial genome [69], adopted a more dediffer-
entiated state than the partially depleted cell types, as 
demonstrated by the expression of early neural develop-
mental genes [18]. Indeed, many key regulators of cell 
proliferation and differentiation were down-regulated 
in the mtDNA-depleted tumours, but up-regulated in 
the mtDNA-depleted cells [18], whilst regulators of 
transcription and differentiation in the Notch signalling 
pathway were up-regulated in the tumours derived from 
mtDNA-depleted cells but down-regulated in the cells 
[18]. Likewise, the regulator of synaptogenesis, APOE, 
was up-regulated in the  GBM50 and  GBM3 tumours 
but down-regulated in the mtDNA-depleted cells [18]. 
Consequently, since the mtDNA-depleted cells recov-
ered their tumorigenicity as mtDNA copy number was 
restored in  vivo, it is evident that the restoration and 
maintenance of mtDNA copy number in tumour-initiat-
ing cells is tightly associated with the regulation of neural 
differentiation in glioblastoma.
The regulation of mtDNA copy number, DNA meth-
ylation and nuclear gene expression at different stages 
of development highlights the need for cells to establish 
a balance between these three components to promote 
their specific fates. In the case of tumours derived from 
cells with different levels of mtDNA, unique DNA meth-
ylation profiles are established that regulate gene expres-
sion and mtDNA copy number in end point tumours (see 
Fig.  7 ‘in vivo’). To this extent,  GBM0.2 cells attempted 
to modulate global DNA methylation patterns and tran-
scription of the  mtDNA replication factors and dif-
ferentiation markers at the expense of tumorigenesis 
resulting in fewer tumours forming and requiring signifi-
cantly longer to form. However,  GBM50 cells were more 
tumorigenic, as they had struck the appropriate balance 
between mtDNA copy number and the methylated state 
of the chromosomal genome to promote tumorigen-
esis. The proposed model shown in Fig. 7 indicates how 
modulation of mtDNA copy number in tumour-initiating 
cells induces changes to DNA methylation of the nuclear 
genome and, therefore, can affect the fate of tumour cells 
in in vitro and in vivo environments. This highlights the 
synergy required between the two genomes in establish-
ing tumorigenesis.
Conclusions
In all, we have shown that the restoration of mtDNA 
copy number during tumorigenesis induces major 
changes to the nuclear genome that resulted in differ-
ential DNA methylation and expression of genes. These 
changes enriched developmental processes and essential 
metabolic pathways associated with GBM. In addition, 
the changes to the nuclear-encoded mtDNA replication 
factors highlight the synergy between the nuclear and 
mitochondrial genomes in restoring tumorigenic capac-
ity. This was clearly demonstrated in the  GBM0.2 tumours 
formed from cells having undergone the highest levels 
of depletion and requiring the longest to initiate tumour 
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formation. They underwent more extensive DNA meth-
ylation remodelling at key CGIs and within the intragenic 
regions of the mtDNA replication factors to maintain 
similar transcriptional levels. Whilst we recognize that 
we have only focused on the HSR-GBM1 tumour model, 
our results highlight the bidirectional control of the 
nuclear and mitochondrial genomes through modulation 
of DNA methylation in response to mtDNA copy num-
ber and to control gene expression in tumorigenesis.
Methods
Cell culture and Xenograft models
GBM tumours were previously generated from HSR-
GBM1 cells possessing different levels of mtDNA copy 
number after treatment with 10  μm 2′–3′-dideoxycy-
tidine (ddC), a mtDNA depletion agent that directly 
inhibits the interaction of POLG with the mitochon-
drial genome [69], in the presence of 50 mg/mL uridine 
(Sigma-Aldrich, MO, USA). Cells were depleted to 50% 
 (GBM50), 3%  (GBM3), 0.2%  (GBM0.2), and 100%  (GBM100) 
of their original mtDNA content, as described in [18]. To 
this extent, HSR-GBM1 cells were cultured in complete 
neural stem cell media consisting of Dulbecco’s Modified 
Eagle Medium/Nutrient Mixture (DMEM/F-12) Media 
(Thermo Fisher Scientific, MA, USA), 2% StemPro neu-
ral supplement (Thermo Fisher Scientific), 20  ng/mL 
basic fibroblast growth factor (bFGF; Merck Millipore 
MO, USA) and 20 ng/mL epidermal growth factor (EGF; 
Merck Millipore) at 37 °C, 5%  CO2 and 95% humidity.
The animal work was approved by the Animal Eth-
ics Committee, Monash University, Approval Number: 
MMCA/2011/76. Briefly, 0.5 million HSR-GBM1 tumour 
cells in 100  mL of medium were inoculated subcutane-
ously into both flanks of 5- to 6-week-old, female BALB/c 
nude mice (Animal Research Centre, Perth, Australia). 
Tumour growth rates and volumes were reported in [18]. 
For each group, cells were injected into 12 mice to form 
tumours, as detailed in [18]. In all, 11 tumours formed 
from  GBM100 cells, 10 from  GBM50 cells, 6 from  GBM3 
cells and 2 from  GBM0.2 cells [18].  GBM100 tumours 
reached an average volume of 175  mm3 at 65  days, 
 GBM50 tumours reached an average volume of 250 mm3 
at 61 days (p > 0.05),  GBM3 tumours reached an average 
volume of ~ 150  mm3 at 83  days (p < 0.01), and  GBM0.2 
tumours reached an average volume of > 200  mm3 at 
90 days (p < 0.01) [18].
DNA extraction
Total genomic DNA was extracted from the tumours 
using the DNeasy Blood & Tissue Kits (Qiagen, CA, 
USA), according to manufacturer’s protocols with minor 
modifications. The DNA samples were treated with 3 μL 
of RNase solution (Qiagen) at room temperature. DNA 
samples were eluted in 100 μL of autoclaved Milli-Q  H2O.
Determination of mtDNA copy number per cell
mtDNA copy number per cell was determined, as pre-
viously described [16]. To this extent, concentrations 
of qPCR products for β-globin and mtDNA were deter-
mined against standard curves generated by quantita-
tive real-time PCR (qPCR; Rotor-Gene 3000, Corbett 
Research, Cambridge, UK) on total DNA purified from 
the tumours (n = 3 per group; n = 3 replicates per sam-
ple). Primer sequences and primer-specific reaction 
conditions are listed in Additional file  3. mtDNA copy 
number per cell was calculated using the formula of 
2 × NmtDNA/Nβ-globin, where, for NmtDNA and Nβ-globin, 
N = (qPCR product concentration × 6.023 × 1014)/(qPCR 
product size in bp × 660).
Immunoprecipitation of methylated DNA sequencing 
(MeDIP‑Seq)
Five microgram of genomic DNA from each of the 
tumour samples (n = 3 per group) underwent MeDIP, as 
previously described [70]. Briefly, each DNA sample was 
sheared into 200–1000  bp using the Covaris Adaptive 
Focused Acoustics (AFA™) S220 system (Woburn, MA, 
USA). dsDNA was then denatured to single-stranded 
DNA, as required for the antibody, by incubation at 95 °C 
for 10 min. 3 μg of each DNA sample was immunopre-
cipitated with 2 μg of anti-5mC antibody (Active Motif ) 
with 20 μL per sample of prewashed  Dynabeads® Protein 
G (Thermo Fisher Scientific). The suspension was incu-
bated in 500 μL of IP buffer (100 mM sodium phosphate 
(pH 7.0); 1.4 M NaCl;0.5% Triton X-100) at 4 °C for 16 h 
under rotation. The beads were then washed three times 
with 1  mL of IP buffer and resuspended in 250  μL of 
proteinase K digestion buffer (50 mM Tris-HCl, pH 8.0; 
10 M EDTA, pH 8.0; 1.0% SDS) with 10 μL of proteinase 
K (20 mg/mL; Bioline, London, UK). The suspension was 
incubated at 50 °C for 3 h on a thermo-shaker. The super-
natant was then collected on a magnetic particle concen-
trator (Thermo Fisher Scientific). DNA was purified from 
the supernatant using the QIAquick PCR Purification Kit 
(Qiagen), according to the manufacturer’s protocol.
MeDIP products from each of the tumour samples 
underwent library construction using the DNA SMART 
ChIP-Seq Kit (Clontech, CA, USA), as per the manu-
facturer’s protocol (No. 021115). Libraries were quality 
checked using Qubit fluorometric quantitation (Thermo 
Fisher Scientific), a 2100 Bioanalyzer (Agilent, CA, USA), 
and qPCR. All libraries were of a similar size (297–
335  bp) and quantities (~ 40  ng/μl). A single equimolar 
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pool was made following denaturation of the libraries 
at 94  °C for 2  min. 12  pM of each library was used for 
onboard cluster generation and sequencing in 4 lanes 
of two consecutive Illumina HiSeq  1500 Rapid runs. 
Cluster densities were within the optimal range of 881–
959  k/mm2 (optimal 750–1000  k/mm2). This resulted 
in around 170 million readable clusters per lane. 95% of 
the clusters passed filter, and 96% of the reads passed 
the Illumina sequencing quality score of Q30, which 
was deemed excellent quality for base-calling. Run qual-
ity parameters with the PhiX spike-in had an error rate 
of 0.12% (expected < 0.5%) and phasing/pre-phasing of 
< 0.13/< 0.10 (expected < 0.4/< 0.2).
Computational analysis for MeDIP‑Seq
Mapping
Computational analysis was performed on the MeDIP-
Seq sequences using the customized analytical pipeline, 
as described in [31]. Briefly, the sequences were firstly 
checked for quality and adaptors using the FastQC soft-
ware (v 0.11.5). The raw sequences were then aligned to 
the human reference genome GRCh38/hg38 (UCSC) 
using the Burrows-Wheeler Aligner (BWA) software 
(version 0.7.16a) in the single-end mode of the BWA-
backtrack algorithm with default settings [71]. The out-
put files (*.sam) were then combined and converted to 
bam files (*.bam) by SAMtools (version 1.4).
Determination of differentially methylated regions (DMRs)
Uniquely mapped reads with mapping scores 
(MAPQ) ≥ 30 were kept for analytical analysis using the 
MEDIPS package (version 1.24.0), according to the com-
mand codes of the MEDIPS package. Briefly, the reads 
were cleaned for PCR duplicates that mapped to exactly 
the same genomic positions by setting the parameter 
“uniq” to 1. The reads were then extended to 500 nucle-
otides according to the reference genome without any 
shift in the genomic locations by setting the parameter 
“extend” to 500 and “shift” to 0. The coverage of every 
100-bp window of the genome was summarized by set-
ting the parameter “window_size” to 100. MeDIP-Seq-
specific quality control analysis was performed on each 
sample, which includes saturation analysis and CpG 
enrichment analysis. A coupling factor was set up based 
on the  GBM100 sample for normalization. Differentially 
methylated windows (DMWs) with the total count of 
reads ≥ 100 (minrowsum = 100) were identified between 
groups using the ‘edgeR’ method. Statistically significant 
DMWs were selected for downstream analysis. Continu-
ous significant DMWs were merged as one DMR (Addi-
tional file 4).
Annotation of DMRs
DMRs then underwent annotation based on their cor-
responding genomic regions in the human genome 
using the ChIPSeeker package (version 3.5) [72]. Super-
enhancer annotation was performed using the dbSUPER 
databases [73]. TAD overlapping analysis was conducted 
using the TAD datasets available in The ENCODE project 
[74]. Gene lists were analysed for gene ontology using the 
Panther Classification System (version 12.0) [75]. The 
functional classification analysis was used to annotate 
the functions of genes. The statistical overrepresentation 
test (Fisher’s exact test with a false discovery rate (FDR) 
correction) was used to identify the significance of asso-
ciated biological processes overrepresented amongst the 
genes.
Region‑of‑Interest (ROI) analysis
DNA methylation levels at particular regions of the 
genome, for example CGIs associated with the mtDNA 
replication factors, were assessed by the built-in ROI 
analysis in the MEDIPS package. DNA methylation levels 
of ROIs were expressed as relative methylation scores, as 
determined by the MEDIPS package. The relative methyl-
ation score was developed specifically for MeDIP-Seq in 
order to normalize methylation scores for regions based 
on the concept of CpG coupling analysis [76, 77].
Determination of copy number variation (CNV)
Total DNA from the tumour samples (n = 3 per group) 
was submitted to the Australian Genome Research 
Facility (AGRF; VIC, AUS) to perform genotyping. The 
Illumina Human Global Screening Array Beadchip (Illu-
mina) was used, which covers approximately 700 K SNPs 
throughout the genome. Array data were normalized, 
clustered and underwent genotype calling using the Gen-
otype Module of GenomeStudio 2.0 (Illumina), according 
to the user’s manual. The full data report containing log 
R ratios and B allele frequencies for each probe was then 
exported and analysed using Nexus 9.0 software (BioDis-
covery Inc., CA, USA). The Nexus Copy Number Module 
was used to identify regions of CN gain and loss, loss of 
heterozygosity (LOH) for each group and statistically sig-
nificant CNVs between groups (p value ≤ 0.05). Human 
genome hg19 was chosen as the reference genome to 
annotate the genomic locations. Genomic regions were 
then aligned to human genome hg38, allowing overlap-
ping analysis with the DMRs using the ‘intersect’ func-
tion of bedtools (v2.24.0) [78, 79].
Identification of DMR‑overlapping differentially expressed 
genes
RNA-Seq was previously performed on the GBM 
tumours [17]. The sequencing files were deposited in the 
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NCBI Sequence Read Archive (SRA) under the accession 
code PRJNA296542 [17]. The sequences were mapped 
to the human genome (hg19) using the Tophat aligner 
(v1.3.1) [17, 80]. Differentially expressed genes were 
determined using the Cufflinks tool (v2.2.1) [17, 80]. Dif-
ferentially expressed genes (FDR ≤ 0.05) underwent lift-
over analysis to match the hg38 human genome assembly 
using the GALAXY platform (usegalaxy.org) and then 
overlapping analysis was performed with the DMRs using 
the ‘intersect’ function of bedtools (v2.24.0) [78, 79].
Gene expression analysis using real‑time quantitative PCR
Total genomic RNA was extracted from the tumour sam-
ples (n = 3 per group) using the RNeasy Mini Kit and the 
QIAshredder (Qiagen, CA, USA), according to manu-
facturer’s protocols with minor modifications. The RNA 
samples were treated with DNase I (Qiagen) on column 
for 20 min. cDNA was synthesized from 1 μg of the total 
RNA using the Superscript III First-Strand synthesis sys-
tem (Thermo Fisher Scientific), according to the manu-
facturer’s instructions.
cDNA products (n = 3 technical replicates per tumour) 
were assessed using the Rotor-Gene 3000 RT-PCR 
machine under primer-specific conditions (Additional 
file  3), as described in [16]. Relative gene expression to 
the  GBM100 tumours was calculated using the ΔΔCT 
method. OAZ1, 18SrRNA and HPRT1 were used as the 
housekeeping genes, of which the mean values of expres-
sion were used as the internal control for data normaliza-
tion [31]. Data were represented as the fold change to the 
 GBM100 group (n = 3; mean ± SEM). One-way ANOVA 
was used to determine statistical significance between 
the  GBM50,  GBM3 and  GBM0.2 tumours and the  GBM100 
tumours. Results were plotted using GraphPad Prism 7 
(GraphPad Software, Inc., CA, USA).
Gene expression analysis using the Fluidigm platform
Using the same sets of cDNA samples (n = 3 per group; 
n = 2 replicates per sample), gene expression of targets 
of interest was assessed using the Fluidigm qPCR array, 
according to the manufacturer’s instructions. Taqman 
primers are listed in Additional file 5. Taqman primers 
were pooled and diluted in C1 DNA suspension buffer 
to a final concentration for each primer of 180  nM. 
Each cDNA sample and a non-template control under-
went pre-amplification for 14 cycles, according to the 
manufacturer’s instructions (Quick Reference PN 100-
5876 B1). The pre-amplification reaction consisted of 
the Taqman PreAmp Master mix (Thermo Fisher Sci-
entific) and the pooled Taqman primers. Products were 
diluted fivefold with C1 DNA suspension buffer. The 
integrated fluidic circuit controller HX was then used 
to prime and load the 96.96 Dynamic array plate. 5 μL 
of each sample was loaded in duplicate into each sample 
inlet and 5 μL of each Taqman assay (10 x) were loaded 
into each assay inlet. Real-time qPCR was performed 
according to the Biomark GE 96.96 Standard v2 proto-
col. Data were exported using the Fluidigm real-time 
PCR analysis software (v4.1.1). Relative gene expression 
was calculated using the same method described above.
Additional files
Additional file 1. MeDIP-Seq specific QC results determined by the 
MEDIPS package.
Additional file 2. Summary of CNV regions identified in each cohort of 
tumours and overlapping with DMRs using the Nexus 9.0 software.
Additional file 3. Primer pairs for real time PCR.
Additional file 4. DMRs identified using MeDIP-Seq and MEDIPS package.
Additional file 5. Taqman assays used in the Fluidigm qPCR arrays.
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